Inve India ▾

Innova Captab share price & results

Innova Captab Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Contract drug manufacturer (CDMO) and branded-generics maker with 9 manufacturing blocks across Baddi, Dehradun, Taloja and Jammu.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue471 ₹ crore+33.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin16.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit44.0 ₹ crore+41.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity15.02 %−0.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.44 %+12.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)34.44 %+16.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 5 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Innova Captab Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (4 achieved, 1 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Jammu Facility Revenue FY26₹400-500 crores
Call transcript, Q3 FY25 · 6 Feb 2025		Q3 FY25Q1 FY27:Promise concluded in FY26. The final outcome was an achievement of the revised (lower) target, but a miss on the original guidance.
Call transcript, Q1 FY27 · 12 Aug 2026		Achieved*
Jammu Plant EBITDA Break-even Sales LevelINR50 crores to INR55 crores in quarterly sales
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Achieved positive EBITDA of ₹1-1.5 crores on revenue of ₹107 crores. This confirms the breakeven sales level was significantly higher than the original ₹50-55 crore guidance.
Call transcript, Q1 FY27 · 12 Aug 2026		Missed
Working Capital Dayscome back to 85-90 days
Call transcript, Q2 FY26 · 10 Nov 2025		Q2 FY26Q1 FY27:Addressed after two quarters of silence. New guidance given for cash conversion cycle at '90 days, plus-minus 10 days' (80-100 days). This is a wider and slightly less favorable range than the original 85-90 days.
Call transcript, Q1 FY27 · 12 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Innova Captab Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Innova Captab Limited's 17 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,062.6 +6.45% · +₹64.4

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +32.0% 1Y

₹0.6k₹0.8k₹1.0k₹1.2kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 27 Jan 2026Q4 FY26 — 8 May 2026Q1 FY27 — 12 Aug 2026

1Y: ₹805.3 on 24 Oct 2025 → ₹1,062.6. High ₹1,297.6 (23 Sept 2026), low ₹644.75 (19 Jan 2026).

Previous close
₹998.2
Market cap
₹5.7k Cr
52-week range
₹644.75 – ₹1,297.6
One year
+32.29%
Price to earnings (TTM to Jun 2026)
37.09×
Return on equity (TTM to Jun 2026)
15.02%

Overview

Symbol
NSE:INNOVACAP
Exchange
NSE
Currency
INR

What Innova Captab Limited does

Based on the company's own presentations, annual report and earnings calls.

Innova Captab is a pharmaceutical company running a dual business model: manufacturing formulations on contract for other pharma companies (CDMO) and selling its own branded generic medicines through a domestic and export distribution network. It also produces active pharmaceutical ingredients (APIs) and offers dosage forms spanning tablets, capsules, liquid orals, ointments, dry syrups, dry powder injectables and parenterals. Its Kathua (Jammu) facility, commercialised in January 2025, added blow-fill-seal parenterals and respiratory respules to its capability base. Revenue is generated both from long-term CDMO manufacturing contracts with pharma clients globally and from direct sale of its own branded generic products.

Segments

  • CDMO Services and Products
  • Branded Generics
Manufacturing blocks
9
Manufacturing units/facilities
5 (Baddi x2, Dehradun, Taloja, Kathua-Jammu)
CDMO customers
350+
Product portfolio
4,200+
Export presence
60+ countries
Domestic distribution touchpoints (pharmacies)
2,50,000+
Founded 2006Headquarters Panchkula, Haryana (registered office: Navi Mumbai, Maharashtra)Employees 3,300 (FY26 (year ended 31 Mar ) Company website

How the price took the results

close before → close after

Q1 FY27
−0.7%
12 Aug
Q4 FY26
+1.4%
8 May
Q3 FY26
+3.4%
27 Jan
Q2 FY26
−3.5%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Innova Captab Limited

Free account: one company. Everything above stays public.

Write why you follow Innova Captab Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Innova Captab Limited

Guides on how to read this kind of business and the numbers that matter.